Galderma Raises Revenue Outlook as Quarterly Sales Beat Consensus
Vontobel says Galderma lifted its revenue outlook for the year more than expected and quarterly sales beat consensus estimates. Investor concerns about skin medication Nemluvio's growth did not materialize, the analyst says.
Galderma's revenue outlook for the year was lifted more than expected and quarterly sales beat consensus estimates, supporting shares in turn, Vontobel says in a research note. Investor concerns that skin medication Nemluvio had a growth issue didn't materialize, Vontobel analyst Stefan Schneider s…